In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

Mark P. GrilloDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA; Correspondence[email protected]

John C. L. ErveDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA;

Ryan DickDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA;

James P. DriscollDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA;

Nicole HasteDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA;

Svetlana MarkovaDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA;

Priscilla BrunSanofi-Aventis Recherche et Développement, Montpellier, France

Timothy J. CarlsonDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA;

Marc EvanchikDepartment of Drug Metabolism and Pharmacokinetics, MyoKardia, Inc, South San Francisco, CA, USA;

Related Research Data